---
id: acr-ra-2024
title: "2024 ACR Guideline for the Treatment of Rheumatoid Arthritis"
short_title: "Rheumatoid Arthritis"
organization: American College of Rheumatology
country: United States
url: https://onlinelibrary.wiley.com/doi/10.1002/art.42715
specialty: rheumatology
guideline_type: clinical-practice
evidence_system: acr-grade
conditions:
  - Rheumatoid Arthritis
  - RA
tags:
  - rheumatoid arthritis
  - DMARDs
  - biologics
  - JAK inhibitors
publication_date: 2024-06-01
previous_version_date: 2021-06-08
status: current
supersedes: acr-ra-2021
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for the pharmacologic treatment of rheumatoid arthritis in adults, including DMARD-naïve and DMARD-experienced patients.

## Key Recommendations

### DMARD-Naïve Patients
**First-Line:**
- Methotrexate monotherapy (strongly recommended)
- Target dose: 15-25 mg weekly with folic acid

**Alternatives (if MTX contraindicated):**
- Leflunomide
- Sulfasalazine
- Hydroxychloroquine (usually in combination)

### Moderate-to-High Disease Activity Despite csDMARD
**Add or Switch to Biologic/tsDMARD:**
- TNF inhibitors: Adalimumab, etanercept, infliximab, certolizumab, golimumab
- IL-6 inhibitors: Tocilizumab, sarilumab
- T-cell co-stimulation inhibitor: Abatacept
- JAK inhibitors: Tofacitinib, upadacitinib, baricitinib

**Recommendations:**
- Biologic DMARD or JAK inhibitor over triple csDMARD therapy
- Combination with MTX preferred for most biologics

### After First bDMARD/tsDMARD Failure
- Switch to different mechanism class
- If failed TNFi: Consider non-TNF biologic or JAKi
- If failed JAKi: Switch to biologic

### Treat-to-Target
- Target: Low disease activity or remission
- Reassess at 3-6 months intervals
- Adjust therapy if target not met

### Glucocorticoids
- Short-term bridge therapy acceptable (≤3 months)
- Use lowest effective dose
- Avoid long-term use due to toxicity

### Special Considerations
**Cardiovascular Risk:**
- JAK inhibitors: Consider CV/VTE risk (age >50, CV risk factors)
- May prefer biologics in high CV risk patients

**Infections:**
- Screen for TB, hepatitis before bDMARD/tsDMARD
- Hold during active infection

**Pregnancy:**
- TNFi (certolizumab, etanercept) compatible
- Discontinue MTX, leflunomide, JAKi
